Smartwatch with heart rate monitor icon on colorful diagonal striped background
Medtech Case Study

Patient-Reported Outcomes Diary Leads to Product Label Update

Patient Input and New Patient-Reported Outcome Measure Support a US Food and Drug Administration Drug Label Update
 

Source
National Health Council; Value in Health

Link(s)
Patient-Focused Medical Product Development Case Examples; Item-Level Psychometric
Properties for a New Patient-Reported Psoriasis Symptom Diary
 

Description of Case Study

Novartis engaged people living with psoriasis and experts on psoriasis through qualitative interviews to identify the symptoms and impacts that mattered most to them, which informed the development of the Psoriasis Symptom Diary, a 20-item, daily patient-reported outcome instrument developed in accordance with the US Food and Drug Administration’s (FDA) patient-reported outcome guidance. The diary was subsequently validated in phase III clinical trials as a secondary endpoint, measuring self-reported itching, pain, and scaling. Data collected using this tool supported an FDA label update for Cosentyx (secukinumab).
 

Quick Facts

Organization name: Novartis
Organization type: pharmaceutical company
Product category: pharmaceutical/biological product
Region(s) of patient engagement activities: North America: United States
Total product life cycle stage(s): clinical/testing, evaluation/authorization, post-
approval surveillance/monitoring

 

Product Type(s)

  • pharmaceutical/biological product
     

Product Medical Specialty Area(s)

  • immunology
  • other: dermatology, rheumatology
     

Stakeholders

  • pharmaceutical company: internal regulatory affairs teams
  • patients and caregivers
  • patient organizations
  • regulators
     

Methods and Sources of Patient Input

  • interviews/focus groups/surveys
  • clinical outcome assessments (patient-reported outcomes, clinician-reported outcomes, observer- reported outcomes)
     

Impact of Patient Engagement

  • Elevating patient-centered outcome measures: Qualitative patient interviews identified itching, pain, burning, stinging, and changes in skin appearance as the symptoms patients experienced as most significant, providing the content foundation for a patient-reported outcome instrument that reflected what patients actually experience rather than only what clinicians observe.
  • Impacting labeling revisions: Data from the Psoriasis Symptom Diary, used as a secondary endpoint in Phase III trials, contributed to an FDA label update for Cosentyx, demonstrating that systematically collected, patient-centered symptom data can directly influence regulatory outcomes.
  • Clinically meaningful responder definitions established for regulatory use: Before the pivotal trials, testing established clear thresholds for what counts as a meaningful improvement on the diary, a step the FDA requires for patient-reported instruments intended to support labeling claims. This meant trial results could be interpreted in terms patients and clinicians actually care about, not just ones of statistical significance.
     

Lessons Learned

  • Patient input elicited early ensures trial endpoints reflect what patients actually experience: Structured interviews conducted before the diary was finalized confirmed it covered the symptoms that mattered most to patients and that patients understood the questions as written. Without this step, important symptoms, ones not captured by standard clinician tools, could easily have been left out of the trial endpoint set.
  • Following FDA’s patient-reported outcomes guidance from the outset is critical for labeling use: The diary was developed and validated following FDA’s guidance from the start, not added to trials as an afterthought, and the resulting data were accepted in support of a label update.
  • Clinician measures and patient-reported measures can assess different dimensions of disease: Standard clinician assessments and patient-reported measures were tracked very differently at the start of the trial but converged as treatment took effect, a pattern that reinforces why both types of data are needed. Clinician tools and patient-reported tools measure different things; one is not a substitute for the other.
  • Psychometric testing was important for refining, not just confirming, instrument content: Several items included in the original draft did not perform well when tested and were removed before the pivotal trials. The willingness to refine the instrument based on evidence, rather than treating the initial item set as final, was essential to producing a credible, regulatory-grade tool. Patient-reported outcome instrument development should be treated as iterative, not a one-time exercise.